![Dominik Ellenrieder](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dominik Ellenrieder
Président chez
Senspec GmbH
Fortune : 78 M $ au 31/05/2026
Profil
Dominik Ellenrieder was the founder of Kuros Biosurgery Holding AG, founded in 2002, where he held the title of Director-Executive Board from 2010 to 2012.
He was also the founder of Kuros Therapeutics AG, founded in 2000, where he served as Chairman from 2000 to 2002.
Currently, Mr. Ellenrieder holds several positions.
Since 2006, he has been Chairman of SenTec AG.
He is also Chairman of Senspec GmbH, Nexmed Holding AG, Le Grand Hotel Chandolin SA, and Operating Partner at Endeavour Vision SA since 2007.
In his former roles, Mr. Ellenrieder served as Chairman of Symetis SA from 2015 to 2017.
He was Vice Chairman of Kuros Biosciences Ltd. and Kuros Biosciences AG from 2003 to 2015.
He also held the position of Vice Chairman at Medartis AG from 2000 to 2021.
Additionally, he was a Director at Straumann Holding AG from 2001 to 2014 and an Independent Non-Executive Director at Medartis Holding AG from 2000 to 2023.
He has also worked at Stratec Medical AGs, Sulzer Medica, and Protek AG in various roles.
Mr. Ellenrieder's education includes an MBA from Boston University, an undergraduate degree from the University of Basel, and an MBA from the Graduate School of Business Administration Zürich.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MEDARTIS HOLDING AG 5,77% | 31/12/2025 | 785 962 ( 5,77% ) | 78 M $ | 31/05/2026 |
Postes actifs de Dominik Ellenrieder
| Sociétés | Poste | Début |
|---|---|---|
Endeavour Vision SA
 Endeavour Vision SA Investment ManagersFinance EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany. Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions. EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired. | Corporate Officer/Principal | 01/09/2007 |
SenTec AG
 SenTec AG Electronic Equipment/InstrumentsElectronic Technology Develops and markets medical related products | Président | 24/02/2012 |
Senspec GmbH | Président | - |
Nexmed Holding AG | Président | - |
Le Grand Hotel Chandolin SA | Président | - |
Anciens postes connus de Dominik Ellenrieder
| Sociétés | Poste | Fin |
|---|---|---|
| MEDARTIS HOLDING AG | Directeur/Membre du Conseil | 01/04/2023 |
Medartis AG | Directeur/Membre du Conseil | 01/01/2021 |
| KUROS BIOSCIENCES AG | Directeur/Membre du Conseil | 01/01/2015 |
Kuros Biosciences AG
 Kuros Biosciences AG Miscellaneous Commercial ServicesCommercial Services Develops products for tissue repair and regeneration | Directeur/Membre du Conseil | 01/01/2015 |
| ░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Dominik Ellenrieder
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
42
Relations au 1er degré
20
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 20 |
|---|---|
Straumann Holding AG
 Straumann Holding AG Medical SpecialtiesHealth Technology Develops, produces and markets products for dental implants and biomaterials for soft and hard tissue generation | Health Technology |
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stratec Medical AGs | |
Sulzer Medica
 Sulzer Medica Medical SpecialtiesHealth Technology Makes orthopedic and cardiovascular products with a focus on implantable medical devices | Health Technology |
Kuros Biosurgery Holding AG
 Kuros Biosurgery Holding AG Miscellaneous Commercial ServicesCommercial Services Discovers and develops drugs for biosurgery, tissue repair and regeneration | Commercial Services |
University of Basel
 University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Symetis SA
 Symetis SA BiotechnologyHealth Technology Develops products for pediatric cardio-vascular applications | Health Technology |
Endeavour Vision SA
Endeavour Vision SA Investment ManagersFinance EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany. Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions. EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired. | Finance |
Graduate School of Business Administration Zürich
 Graduate School of Business Administration Zürich Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Medartis Holding AG
 Medartis Holding AG Medical SpecialtiesHealth Technology Designs and manufactures orthopedic devices | Health Technology |
SenTec AG
SenTec AG Electronic Equipment/InstrumentsElectronic Technology Develops and markets medical related products | Electronic Technology |
Kuros Therapeutics AG | |
Qgel SA
 Qgel SA BiotechnologyHealth Technology Engages in drug discovery | Health Technology |
Senspec GmbH | |
Kuros Biosciences Ltd.
 Kuros Biosciences Ltd. BiotechnologyHealth Technology Develops biological products for tissue repair | Health Technology |
Nexmed Holding AG | |
Le Grand Hotel Chandolin SA | |
Kuros Biosciences AG
Kuros Biosciences AG Miscellaneous Commercial ServicesCommercial Services Develops products for tissue repair and regeneration | Commercial Services |
Medartis AG | |
Protek AG |
